News | July 28, 2023
Laurus Labs posts decline in Q1FY24 consolidated PAT to Rs. 24.85 Cr
The company has reported total income of Rs. 1185.39 crores during the period ended June 30, 2023
The company has reported total income of Rs. 1185.39 crores during the period ended June 30, 2023
Laurus Labs has announced that the USFDA completed inspection of the formulations manufacturing facility Unit-2, APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.
This will enable the company to consume 100% of the solar energy to be supplied by Ethan Energy India Private Limited from their 10 MW Solar Energy plant
The observation is procedural in nature and the company will address the observation within stipulated timelines.
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
Subscribe To Our Newsletter & Stay Updated
